Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NBTX Stock Forecast 2025-2026
$3.86
Current Price
$187.56M
Market Cap
Buy 3
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to NBTX Price Targets
+130.1%
To High Target of $8.88
+114.8%
To Median Target of $8.29
-3.5%
To Low Target of $3.73
NBTX Price Momentum
+13.2%
1 Week Change
+17.3%
1 Month Change
-46.6%
1 Year Change
+34.5%
Year-to-Date Change
-48.6%
From 52W High of $7.51
+39.9%
From 52W Low of $2.76
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Nanobiotix (NBTX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NBTX and similar high-potential opportunities.
Latest NBTX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, NBTX has a bullish consensus with a median price target of $8.29 (ranging from $3.73 to $8.88). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $3.86, the median forecast implies a 114.8% upside. This outlook is supported by 3 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NBTX Analyst Ratings
3
Buy
1
Hold
0
Sell
NBTX Price Target Range
Low
$3.73
Average
$8.29
High
$8.88
Current: $3.86
Latest NBTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NBTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 4, 2025 | Guggenheim | Michael Schmidt | Buy | Maintains | $8.00 |
| Aug 28, 2024 | Guggenheim | Michael Schmidt | Buy | Initiates | $12.00 |
| Dec 8, 2023 | Leerink Partners | Jonathan Chang | Outperform | Initiates | $11.00 |
| Jan 6, 2021 | Evercore ISI Group | Jonathan Miller | Outperform | Initiates | $0.00 |
Nanobiotix S.A. - ADR (NBTX) Competitors
The following stocks are similar to Nanobiotix based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Nanobiotix S.A. - ADR (NBTX) Financial Data
Nanobiotix S.A. - ADR has a market capitalization of $187.56M with a P/E ratio of -2.7x. The company generates $-8,055,028 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of +271.4% and return on equity of +103.7%.
Valuation Metrics
Market Cap
$187.56M
Enterprise Value
$196.21M
P/E Ratio
-2.7x
PEG Ratio
-1.5x
Price/Sales
-26.1x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
+271.4%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+27.2%
Current Ratio
1.0x
Debt/Equity
-0.9x
ROE
+103.7%
ROA
-52.9%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Nanobiotix S.A. - ADR (NBTX) Business Model
About Nanobiotix S.A. - ADR
What They Do
Develops innovative cancer treatment solutions using nanomedicine.
Business Model
Nanobiotix S.A. operates by enhancing existing radiotherapy methods, particularly through its NanoXray platform, which improves the precision of targeting cancer cells while protecting healthy tissues. The company generates revenue by offering these advanced treatment solutions, making it an attractive investment for those interested in innovative healthcare technology.
Additional Information
Nanobiotix engages in cross-border investment opportunities through American Depositary Receipts (ADRs), allowing U.S. investors to easily participate in its growth. The company's focus on improving patient outcomes for various solid tumors positions it to potentially redefine standard care protocols in oncology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
108
CEO
Mr. Laurent Levy Ph.D.
Country
France
IPO Year
2020
Website
www.nanobiotix.comNanobiotix S.A. - ADR (NBTX) Latest News & Analysis
Latest News
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
5 days ago
Quick Summary
NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX) will participate in fireside chats at an upcoming conference, focusing on its nanoparticle-based cancer treatment advancements.
Why It Matters
Management's participation in conferences can signal potential advancements and investor interest, influencing stock performance and market perception of NANOBIOTIX's growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NANOBIOTIX's Phase 1 study of JNJ-1900 (NBTXR3) in 22 pancreatic cancer patients showed a median overall survival of 23 months and 13.3 months progression-free survival. Further evaluation is planned.
Why It Matters
Positive trial results for JNJ-1900 in pancreatic cancer suggest potential for improved treatment outcomes, which may enhance investor confidence and drive stock performance for NANOBIOTIX.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NANOBIOTIX will present full results from a Phase 1 study of JNJ-1900 (NBTXR3) for pancreatic cancer at the ESTRO 2025 meeting on May 4. The study was conducted by MD Anderson Cancer Center.
Why It Matters
The presentation of Phase 1 study results for NBTXR3 in pancreatic cancer could significantly impact NANOBIOTIX's stock, influencing investor sentiment and potential market performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
JNJ-1900 (NBTXR3) is advancing in oncology, targeting head and neck and lung cancers. Financial stability is enhanced with a cash runway extending to mid-2026 and a planned conference call on April 3, 2025.
Why It Matters
The progress of JNJ-1900 in oncology, extended cash runway, and reduced cash burn enhance financial stability, signaling potential for growth in a significant market, which could drive investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Nanobiotix S.A. will hold a Q4 2024 results conference call on April 3, 2025, at 8:00 AM ET, featuring key company executives and analysts from various firms.
Why It Matters
Nanobiotix's Q4 2024 results could reveal financial health and growth prospects, influencing stock performance and investor sentiment in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
1 month ago
Quick Summary
A conference call and webcast is scheduled for April 3, 2025, at 8:00 am EDT / 2:00 pm CEST.
Why It Matters
The scheduled conference call may signal upcoming financial updates or strategic announcements, influencing stock prices and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About NBTX Stock
What is Nanobiotix S.A. - ADR's (NBTX) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Nanobiotix S.A. - ADR (NBTX) has a median price target of $8.29. The highest price target is $8.88 and the lowest is $3.73.
Is NBTX stock a good investment in 2025?
According to current analyst ratings, NBTX has 3 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.86. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NBTX stock?
Wall Street analysts predict NBTX stock could reach $8.29 in the next 12 months. This represents a 114.8% increase from the current price of $3.86. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Nanobiotix S.A. - ADR's business model?
Nanobiotix S.A. operates by enhancing existing radiotherapy methods, particularly through its NanoXray platform, which improves the precision of targeting cancer cells while protecting healthy tissues. The company generates revenue by offering these advanced treatment solutions, making it an attractive investment for those interested in innovative healthcare technology.
What is the highest forecasted price for NBTX Nanobiotix S.A. - ADR?
The highest price target for NBTX is $8.88 from at , which represents a 130.1% increase from the current price of $3.86.
What is the lowest forecasted price for NBTX Nanobiotix S.A. - ADR?
The lowest price target for NBTX is $3.73 from at , which represents a -3.5% decrease from the current price of $3.86.
What is the overall NBTX consensus from analysts for Nanobiotix S.A. - ADR?
The overall analyst consensus for NBTX is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $8.29.
How accurate are NBTX stock price projections?
Stock price projections, including those for Nanobiotix S.A. - ADR, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 18, 2025 12:22 AM UTC